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Ganoderma lucidum reduces obesity in mice by
modulating the composition of the gut microbiota
Chih-Jung Chang1,2,3,4,5,*, Chuan-Sheng Lin1,2,3,5,*, Chia-Chen Lu6, Jan Martel1, Yun-Fei Ko7,8, David M. Ojcius1,9,
Shun-Fu Tseng5, Tsung-Ru Wu2,3, Yi-Yuan Margaret Chen4, John D. Young1,7,8,10 & Hsin-Chih Lai1,2,3,5
Obesity is associated with low-grade chronic inflammation and intestinal dysbiosis.
Ganoderma lucidum is a medicinal mushroom used in traditional Chinese medicine with
putative anti-diabetic effects. Here, we show that a water extract of Ganoderma lucidum
mycelium (WEGL) reduces body weight, inflammation and insulin resistance in mice fed a
high-fat diet (HFD). Our data indicate that WEGL not only reverses HFD-induced gut
dysbiosis—as indicated by the decreased Firmicutes-to-Bacteroidetes ratios and endotoxin-
bearing Proteobacteria levels—but also maintains intestinal barrier integrity and reduces
metabolic endotoxemia. The anti-obesity and microbiota-modulating effects are transmissible
via horizontal faeces transfer from WEGL-treated mice to HFD-fed mice. We further show
that high molecular weight polysaccharides (4300 kDa) isolated from the WEGL extract
produce similar anti-obesity and microbiota-modulating effects. Our results indicate that
G. lucidum and its high molecular weight polysaccharides may be used as prebiotic agents to
prevent gut dysbiosis and obesity-related metabolic disorders in obese individuals.
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T
raditional Chinese Medicine has a long history in Asian
countries dating back several thousands of years1,2. One
class of traditional remedies commonly in use consists of
medicinal mushrooms such as Ophiocordyceps sinensis, Antrodia
cinnamomea and Agaricus blazei Murrill, which contain a wide
range of immuno-modulatory and bioactive compounds3,4. One
of the most intriguing medicinal mushrooms is the Basidiomycete
fungus Ganoderma lucidum, which has been used for centuries to
promote health and longevity5. Previous studies have shown
that triterpenes and polysaccharides isolated from G. lucidum
inhibit adipocyte differentiation6 and produce hypoglycaemia
effects in diabetic mice7. In addition, proteoglycans isolated from
G. lucidum fruiting bodies induce antidiabetic, antihyperlipidemic
and antioxidant activities8. However, it remained unknown
whether G. lucidum produces any effect on body weight and
obesity-related disorders.
Obesity is defined as a disease condition associated with
numerous health problems and a reduced life expectancy9.
Growing evidence indicates that obesity is closely linked with
chronic, low-grade inflammation, which can lead to insulin
resistance, type 2 diabetes, fatty liver disease, cardiovascular
disease, obstructive sleep apnoea and cancer10,11. The high
prevalence of obesity is currently a major threat to public health,
with B500 million obese people and 1.4 billion overweight
individuals worldwide12. Prevention of obesity thus represents a
major challenge for modern societies.
A recent study indicates that changes in the composition of the
gut microbiota are associated with the development of obesity
and its associated metabolic disorders13. The gut microbiota
comprises trillions of bacteria that contribute to nutrient
acquisition and energy regulation14,15. An increased ratio of the
major phyla Firmicutes/Bacteroidetes and changes in several
bacterial species can promote the development of obesity in both
dietary and genetic models of obesity in mice16,17. Other studies
in obese animals suggest that obesity-induced gut dysbiosis
caused by either environmental or genetic factors impairs
intestinal integrity18,19. This process leads to the release of the
endotoxin lipopolysaccaride (LPS) from intestinal Gram-negative
bacteria into the bloodstream20, in turn, leading to metabolic
inflammation and insulin resistance in obese mice21 due to
stimulation of Toll-like receptor 4 (TLR4)-mediated
inflammation22. Moreover, chronic injection of LPS in mice
leads to mild obesity and insulin resistance21, highlighting a
possible role for microbiota-derived LPS in obesity-induced
inflammation.
A number of treatments, including antibiotics and prebio-
tics18,19, are being evaluated for the management of obesity and
its related metabolic disorders23. For example, antibiotic
treatment alters the gut microbiota, reduces blood endotoxemia
and improves glucose tolerance in mice lacking the leptin gene
(ob/ob mice) or in mice fed with a HFD19. In addition, prebiotics
are non-digestible, fermentable carbohydrates and fibres, which
reduce body weight and exert anti-inflammatory effects mainly by
enhancing the growth of specific beneficial bacteria found in the
gut24,25. Prebiotics not only alter the intestinal microbiota but
also improve intestinal tight junction integrity and decrease blood
endotoxemia caused by LPS18. Prebiotics may, therefore, protect
animals against obesity-induced inflammation.
In the present study, we examined whether a water extract of
G. lucidum mycelium (WEGL) can decrease obesity in HFD-fed
mice. Our results indicate that WEGL reduces obesity and
inflammation in the treated mice. These effects are transmissible
to HFD-fed mice through horizontal faeces transplantation,
indicating that the effects of WEGL involve the gut microbiota.
Characterization of WEGL showed that polysaccharides of
molecular weight 4300 kDa exerted similar ameliorative effects
as WEGL. These results implied that the high molecular weight
polysaccharides may be the active components of WEGL. Our
data thus demonstrate that WEGL represents a potential prebiotic
agent that may be used for the treatment of obesity and its
complications.
Results
WEGL prevents HFD-induced obesity in mice. Using a mouse
model of obesity, we observed that HFD feeding for 8 weeks led
to significant increases in body and liver weight, epididymal and
subcutaneous fat accumulation, and lipid deposition in adipocytes
and hepatocytes compared with control chow feeding (Fig. 1a–g).
While 8% WEGL did not produce any apparent effects in chow-
fed mice, supplementation with WEGL decreased weight gain and
fat accumulation in a dose-dependent manner in HFD-fed mice
(Fig. 1a–g). Mean energy intake, stool fat and faeces energy did
not vary significantly between HFD-fed groups (Supplementary
Fig. 1), suggesting that the effects of WEGL on body weight and
obesity parameters were not due to reduced food consumption or
energy extraction. These results imply that WEGL reduces weight
gain and fat accumulation in HFD-fed mice.
WEGL reduces inflammation in HFD-fed mice. Previous stu-
dies have shown that HFD-fed obese mice produce higher levels
of pro-inflammatory cytokines in hepatic and adipose tissues,
including tumour necrosis factor-alpha (TNF-a), interleukin-1-
beta (IL-1b), interleukin-6 (IL-6) and plasminogen activator
inhibitor-1 (PAI-1; ref. 26). In contrast, production of the anti-
inflammatory cytokine IL-10 is reduced in obese animals27. We
measured messenger RNA (mRNA) expression of these cytokines
after 8 weeks of HFD feeding with or without WEGL
supplementation. TNF-a, IL-1b, IL-6 and PAI-1 expression
levels were higher in hepatic and adipose tissues of HFD-fed mice
compared with tissues of control chow-fed mice, whereas IL-10
expression was reduced (Fig. 2a–e). Notably, the expression
pattern of these cytokines was altered in a dose-dependent
manner by WEGL treatment, resulting in expression levels closer
to that of chow-fed mice than HFD-fed mice with increasing
WEGL dose (Fig. 2a–e). Moreover, WEGL reduced the levels of
secreted TNF-a, IL-1b and IL-6 proteins in a dose-dependent
manner in the serum of HFD mice (Supplementary Fig. 2).
Obesity is characterized by infiltration and activation of
immune cells in hepatic and adipose tissues28. M1
macrophages, which are recruited by monocyte chemoattractant
protein-1 (MCP-1), are associated with chronic, low-grade
inflammation in adipose tissues of obese animals26. As MCP-1
mRNA expression decreased in the liver and adipose tissues of
HFD-fed mice following treatment with WEGL (Supplementary
Fig. 3a), we examined the numbers of macrophages recruited into
hepatic and adipose tissues using flow cytometry analysis. Double
staining of macrophages with anti-F4/80 antibody combined with
either anti-CD11b antibody (for liver macrophages, also called
Kupffer cells) or anti-CD11c antibody (for macrophages in
adipose tissues) was used for these experiments. Higher levels of
macrophages were detected in hepatic and adipose tissues of HFD
mice compared with chow-fed mice (Supplementary Fig. 3b,c).
While macrophage levels increased following the treatment with
8% WEGL in chow-fed mice, these cells were reduced in a dose-
dependent manner by WEGL in hepatic and adipose tissues of
HFD-fed mice (Supplementary Fig. 3b,c).
Previous studies indicated that HFD feeding also produces a
gradual loss of regulatory T (Treg) cells compared with chow-fed
mice26. While HFD also reduced Treg levels in our mouse model,
supplementation with WEGL led to dose-dependent increases of
Treg cells in liver and adipose tissues of HFD mice
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Figure 1 | WEGL reduces body weight and fat accumulation in HFD-fed mice. Chow- and HFD-fed mice were treated daily with 100ml of either water or
WEGL at 2, 4 or 8% (w/v) by intragastric gavage for two months (n¼ 7 for each group). Effects of WEGL treatment on body weight (a) body weight gain
(b) epididymal fat (c) subcutaneous fat (d) and epididymal adipocyte size (e) are shown. In e, adipocyte size was estimated using the Image J software
(lower panel). Scale bar, 50mm. Liver weight was measured in HFD and control, chow-fed mice (f). Liver lipid content was assessed using oil red O staining
(g). Scale bar, 30mm. Data are expressed as mean±s.e.m. Body weight differences in a were analysed using unpaired two-tailed Student’s t-test
(**Po0.01, ***Po0.001). Graph bars in b, c, d and f marked with different letters on top represent statistically significant results (Po0.05) based on
Newman–Keuls post hoc one-way ANOVA analysis, whereas bars labelled with the same letter correspond to results that show no statistically significant
differences. In the case where two letters are present on top of the bar in b, each letter should be compared separately with the letters of other bars to
determine whether the results show statistically significant differences.
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(Supplementary Fig. 3d,e). In addition, chow-fed mice treated
with 8% WEGL showed increased Treg levels compared
with untreated chow-fed mice (Supplementary Fig. 3d,e). These
results indicate that WEGL reduces inflammation in HFD-fed
mice by reducing macrophage infiltration and enhancing Treg
accumulation in hepatic and adipose tissues.
WEGL reduces endotoxemia and insulin resistance in HFD mice.
Endotoxemia and TLR4 signalling control the production of pro-
inflammatory cytokines in target tissues and lead to chronic
inflammation and insulin resistance in HFD-fed mice19. We
examined the effects of WEGL on LPS serum levels (that is,
endotoxemia) and TLR4 protein expression in hepatic and adipose
tissues. WEGL reduced endotoxemia and TLR4 protein expression
in HFD-fed mice compared with HFD alone (Fig. 3a–c). Since
TLR4 signalling pathways induce the production of pro-
inflammatory cytokines by modulating the activity of JNK and
NF-kB29,30, we examined whether these pathways are affected by
WEGL supplementation. As shown in Fig. 3d,e, WEGL inhibited
JNK phosphorylation in hepatic and adipose tissues of HFD-fed
mice. Moreover, the production of IkB-a, whose interaction with
NF-kB prevents NF-kB translocation and activation, was enhanced
by WEGL treatment (Fig. 3f,g).
Given that enhanced activation of JNK and NF-kB pathways
may induce insulin resistance via phosphorylation of insulin
receptor substrate-1 (IRS-1) on serine 307 and dephosphorylation
of Akt31, we examined the effects of WEGL on insulin activity. As
shown in Supplementary Fig. 4a–e, WEGL treatment reduced
fasting insulin and glucose levels and decreased glucose and
insulin resistance in HFD-fed mice. Accordingly, phosphorylation
of serine 307 on IRS-1 was inhibited by WEGL in hepatic and
adipose tissues, whereas phosphorylation of Akt was enhanced by
the mycelium extract (Supplementary Fig. 4f–i). WEGL therefore
reduces endotoxemia and prevents insulin resistance in HFD-fed
mice.
WEGL regulates lipogenic gene expression. Previous studies
have shown that the expression of genes involved in lipid
Chow
Chow+8%
HFD+8%
HFD+4%
HFD+2%
HFD
Chow
Chow+8%
HFD+8%
HFD+4%
HFD+2%
HFD
Chow
Chow+8%
HFD+8%
HFD+4%
HFD+2%
HFD
3.0
2.5
2.0
1.5
1.0
0.5
0.0
TN
F-
α
 
m
R
N
A
(R
ela
tiv
e
 e
xp
re
ss
io
n)
IL
-6
 m
RN
A
(R
ela
tiv
e
 e
xp
re
ss
io
n)
PA
I-1
 m
R
N
A
(R
ela
tiv
e
 e
xp
re
ss
io
n)
a
a a a
a
a
b
b
c
cd
e
5
4
3
2
1
0
Liver Adipose tissue
Liver Adipose tissue
Liver Adipose tissue
a
a a a a a
c
c
Chow
Chow+8%
HFD+8%
HFD+4%
HFD+2%
HFD
IL
-1
0 
m
RN
A
(R
ela
tiv
e
 e
xp
re
ss
io
n)
a a
a
b
c
d d
e
Liver Adipose tissue
a.d a.d
b
a.c
3.5
2.5
2.0
1.5
1.0
0.5
0.0
5
4
3
2
1
0
b
b
d
a
a
a a a
a
a
a.c
a.c
b
c
c
Chow
Chow+8%
HFD+8%
HFD+4%
HFD+2%
HFD
IL
-1
β m
R
N
A
(R
ela
tiv
e
 e
xp
re
ss
io
n)
a a a a a
b
b
c c
d
d e
6
5
4
3
2
1
0
Liver Adipose tissue
b
Figure 2 | WEGL decreases pro-inflammatory cytokine expression in the liver and adipose tissues of HFD-fed mice. Animals were treated as in Fig. 1.
Relative expression of TNF-a (a), IL-1b (b), IL-6 (c), IL-10 (d) and PAI-1 (e) in hepatic and adipose tissues was assessed using qRT–PCR and in comparison
with the Chow group. Data are shown as mean±s.e.m. Graph bars with different letters on top represent statistically significant results (Po0.05) based on
Newman–Keuls post hoc one-way ANOVA analysis, whereas bars with the same letter correspond to results that show no statistically significant
differences. In the case where two letters are present on top of the bars in d,e, each letter should be compared separately with the letters of other bars to
determine whether the results show statistically significant differences.
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biosynthesis such as acetyl-CoA carboxylase-1, fatty acid
synthase, sterol regulatory element-binding protein-1 and
peroxisome proliferator-activated receptors-g is enhanced in
hepatic and adipose tissues of HFD-fed mice32,33. Our results
indicated that 8% WEGL did not significantly affect the
expression of these genes in chow-fed mice (Supplementary
Fig. 5a–d). In contrast, WEGL reduced lipogenic gene expression
in a dose-dependent manner in HFD-fed mice (Supplementary
Fig. 5a–d).
Increased levels of free fatty acids (FFA) in the blood of obese
animals are thought to arise from a larger mass of adipose
tissue and enhanced inflammation in HFD-fed mice34.
These circulating fatty acids also induce TLR4 signalling in
target tissues and cause insulin resistance22. We observed that
WEGL reduced serum FFA levels in HFD mice (Supplementary
Fig. 5e). WEGL may thus reduce fat accumulation by inhibiting
adipogenic gene expression and decreasing serum FFA in
HFD-fed mice.
WEGL reverses HFD-induced gut dysbiosis. The gut microbiota
of obese humans and HFD-fed mice is characterized by an
increased Firmicutes-to-Bacteroidetes ratio, elevated endotoxin-
producing Proteobacteria, and reduced immuno-homeostatic
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bacterial species35,36. We examined the effects of WEGL on gut
microbiota composition by performing a pyrosequencing-based
analysis of bacterial 16S rRNA (V3–V5 region) in caecal faeces.
After removing unqualified sequences (see Methods), a total of
691,370 raw reads and an average of 16,461±5,411 reads per
sample were obtained. After selecting the effective reads, a total of
292,952 effective reads was generated and each faecal sample
(n¼ 7 for each group) produced an average of 6,975±2,192
effective reads. Samples with a low number of effective reads
(o3,000) were not observed. Rarefaction and Shannon index
analyses indicated that the sequencing depth covered rare new
phylotypes and most of the diversity (Supplementary Fig. 6).
UniFrac-based principal coordinates analysis (PCoA) revealed
a distinct clustering of microbiota composition for each treatment
group (Fig. 4a). Multivariate analysis of variance of PCoA matrix
scores indicated a statistically significant separation between the
microbiota of Chow and Chowþ 8% WEGL groups (Fig. 4b).
Significant separations were also noted for HFD, HFDþ 4%
WEGL and HFDþ 8% WEGL groups (Fig. 4b). On the other
hand, the gut microbiota of HFDþ 2% WEGL mice did not
significantly differ from that of HFD mice (Fig. 4b), consistent
with the mild effects produced by 2% WEGL (Figs 1–3). Notably,
taxonomic profiling demonstrated that treatment with 4% and
8% WEGL reduced the ratio of Firmicutes to Bacteroidetes and
the Proteobacteria phylum in HFD-fed mice to levels similar to
that of chow-fed mice (Fig. 4c). Here as well, the changes
produced by the 2% WEGL treatment were not observed
(Fig. 4c).
We used redundancy analysis (RDA) to identify the specific
bacterial phylotypes that were altered by HFD feeding and WEGL
treatment. Compared with chow-fed mice, HFD feeding sig-
nificantly altered 209 operational taxonomic units (OTUs),
producing 44 increased and 165 decreased OTUs
(Supplementary Data 1 and Supplementary Fig. 7a). In HFD-
fed mice, supplementation with 2, 4 and 8% WEGL, respectively,
altered 44 (24 increased and 20 decreased), 42 (24 increased and
18 decreased) and 56 OTUs (24 increased and 32 decreased;
Supplementary Data 2 and Supplementary Fig. 7b–d), resulting in
significant changes in a total of 91 distinct OTUs (Fig. 4d).
Among the 91 OTUs that were altered compared with HFD-fed
mice, 2, 4 and 8% WEGL treatments altered OTUs in the same
direction in Chow mice for 18, 17 and 30 OTUs, respectively
(Fig. 4e, highlighted with black stars). These results suggest that
8% WEGL is the most effective treatment for modulating the gut
microbiota in our model.
Detailed analysis of the 30 OTUs reversed by 8% WEGL
indicated that Mucispirilum shaedleri37, Escherichia fergusonii
(Proteobacteria20), Enterococcus spp.38, Lactococcus lactis39,
Clostridium lactatifermentans (Clostridium XIVb) and
Oscillibacter valericigenes25,40 (which were found to be enhanced
by HFD and to positively correlate with obesity in the previous
studies cited above) were all reversed by 8% WEGL (Fig. 4d,e).
Notably, in comparison with HFD mice, 8% WEGL treatment
enhanced a variety of bacterial species that negatively correlate
with obesity, including Parabacteroides goldsteinii, Bacteroides
spp., Anaerotruncus colihominis, Roseburia hominis, Clostridium
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Figure 4 | WEGL alters microbiota composition in HFD-fed mice. Microbiota composition in faeces of chow-fed mice treated with or without 8% WEGL
and HFD mice treated with 2, 4 or 8% WEGL were analysed using next generation sequencing (n¼ 7 for each group). (a) Plots shown were generated
using the weighted version of the UniFrac-based PCoA. (b) Multivariate analysis of variance from PCoA matrix scores. (c) Bacterial taxonomic profiling in
the phylum level of intestinal bacteria from different mouse groups. (d) Heatmap showing the abundance of 91 OTUs significantly altered by WEGL in HFD-
fed mice based on RDA. (e) Represented bacterial taxa information (species, genus, family and phylum) of 91 OTUs from d are shown. White circles and
black diamonds indicate the OTUs that increased or decreased in Chow- and HFDþWEGL-fed groups relative to the HFD-fed group. Black stars represent
OTUs whose abundance in chow-fed mice was altered by HFD and then reversed by WEGL. OTU taxonomy is shown on the right.
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methylpentosum (Clostridium IV), Clostridium XIVa and XVIII
and Eubacterium coprostanoligenes (Fig. 4d,e and Supplementary
Data 2; note that these species were initially reduced by HFD
compared with chow feeding). Bacterial species including E.
coprostanoligenes, C. methylpentosum, P. goldsteinii, Bacteroides
spp., A. colihominis, R. hominis and Clostridium XIVa and XVIII
were also enriched in the Chowþ 8% WEGL treatment compared
with the chow diet (Supplementary Data 3 and Supplementary
Fig. 7e). Moreover, many bacterial species increased in the 8%
WEGL group but were not altered by HFD, indicating that WEGL
may enrich specific bacterial species (Fig. 4e and Supplementary
Data 2). Collectively, these results show that WEGL modulates the
gut microbiota of HFD-fed mice, resulting in a microbiota
composition similar to that of chow-fed mice.
WEGL maintains intestinal integrity in HFD mice. Given that
intestinal dysbiosis in HFD-fed animals may affect gut perme-
ability and subsequently lead to release of bacterial LPS into the
circulation19, we examined whether WEGL modulates gut
integrity. While HFD feeding reduced expression of the tight
junction components, zonula occludens-1 (ZO-1) and occludin,
these effects were reversed by WEGL supplementation
(Supplementary Fig. 8). These findings suggest that WEGL may
improve intestinal barrier integrity in HFD-fed mice.
WEGL faecal transplants reduce obesity. Recent studies have
shown that the ability of the gut microbiota to modulate obesity
can be transferred to other animals13. To determine whether the
HFD+
8% WEGL
H
FD
+8
%
 W
EG
L
H
FD
+2
%
 W
EG
L
H
FD
+4
%
 W
EG
L
HFD+
2% WEGL
HFD+
4% WEGLChow HFD
1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2 3 4 5 6 7 1 2 3 4 5 6 7
OTU00001
OTU00002
OTU00006
OTU00012
OTU00009
OTU00008
OTU00014
OTU00019
OTU00084
OTU00025
OTU00059
OTU00071
OTU00055
OTU00068
OTU00057
OTU00075
OTU00052
OTU00097
OTU00083
OTU00236
OTU00099
OTU00158
OTU00129
OTU00111
OTU00155
OTU00208
OTU00261
OTU00195
OTU00308
OTU00360
OTU00254
OTU00291
OTU00305
OTU00324
OTU00396
OTU00433
OTU00522
OTU00545
OTU00567
OTU00382
OTU00428
OTU00470
OTU00493
OTU00404
OTU00499
OTU00569
OTU00575
OTU00686
OTU00705
OTU00710
OTU00716
OTU00718
OTU00719
OTU00735
OTU00758
OTU00786
OTU00013
OTU00004
OTU00033
OTU00017
OTU00040
OTU00011
OTU00015
OTU00026
OTU00024
OTU00090
OTU00049
OTU00027
OTU00037
OTU00036
OTU00044
OTU00106
OTU00146
OTU00054
OTU00127
OTU00174
OTU00144
OTU00199
OTU00107
OTU00175
OTU00263
OTU00265
OTU00268
OTU00297
OTU00373
OTU00284
OTU00610
OTU00615
OTU00647
OTU00720
OTU00745
Species Genus Family Phylum
Ch
ow
- Parabacteroides goldsteinii (T)
- Eubacterium coprostanoligenes (T) HL
- Aneerotruncus colihominis (T) 14565
- Roseburia hominis (T) type strain: A2-183
- Clostridium sporosphaeroides (T) DSM_1294
- Clostridium methylpentosum (T) DSM 5476
- Clostridium lactatifermantans (T) G17
- Clostridium scindens (T) ATCC 35704
- Mucispirillum schaedleri (T) HRI I17
- Escherichia fergusonii (T) ATCC35469
- Enterococcus faecalis (T) JCM 5803
- Oscillibacter valericigenes (T) Sjm18-20 (=NBRC 101213)
- Lactococcus lactis (T) NCDO 607T
- Staphylococcus saprophyticus (T) ATCC 15305
- Parabacteroides
- Bacteroides
Bacteroidetes
- Bacteroidetes
- Clostridium XIVa
- Clostridium XVIII
- Eubacterium
- Anaerotruncus
- Clostridium XIVa
- Clostridium XIVa
- Clostridium III
- Clostridium IV
- Clostridium IV
- Clostridium XIVa
- Clostridium XIVb
- Clostridium IV
- Roseburia
- Bacteroides
- Mucispirillum
- Escherichia
- Enterococcus
- Oscillibacter
- Lactococcus
- Staphylococcus
- Paenibacillus
- Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
- Firmicutes
- Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
- Unclassified Clostridiales
- Unclassified Clostridiales
- Unclassified Clostridiales
- Unclassified Clostridiales
- Unclassified Clostridiales
- Unclassified Clostridiales
Unclassified Clostridiales
- Unclassified Clostridiales
Unclassified Clostridiales
- Unclassified Clostridiales
- Unclassified Mollicutes
- Unclassified bacteria
- Unclassified bacteria
- Unclassified bacteria
- Unclassified bacteria
- Unclassified bacteria
- Unclassified bacteria
- Unclassified bacteria
- Tenericutes
- Actinobacteria
- Deferribacteres
- Proteobacteria
- Lachnospiraceae
Lachnospiraceae
- Lachnospiraceae
- Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
- Lachnospiraceae
- Lachnospiraceae
- Lachnospiraceae
- Lachnospiraceae
- Lachnospiraceae
- Lachnospiraceae
- Lachnospiraceae
Lachnospiraceae
- Lachnospiraceae
- Lachnospiraceae
Lachnospiraceae
- Lachnospiraceae
- Lachnospiraceae
- Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
- Lachnospiraceae
- Prophyromonadaceae
- Bacteroidaceae
- Bacteroidaceae
- Erysipelotrichaceae
- Eubacteriaceae
- Ruminococcaceae
- Ruminococcaceae
- Ruminococcaceae
- Ruminococcaceae
- Ruminococcaceae
- Ruminococcaceae
- Ruminococcaceae
Ruminococcaceae
Ruminococcaceae
- Ruminococcaceae
- Ruminococcaceae
- Ruminococcaceae
- Ruminococcaceae
- Ruminococcaceae
- Ruminococcaceae
- Coriobacteriaceae
- Peanibacillaceae 1
- Staphylococcaceae
- Streptococcaceae
- Enterococcaceae
- Enterobacteraceae
- Deferribacteraceae
More abundant in Chow group and HFD+WEGL groups relative to HFD group
Less abundant in Chow group and HFD+WEGL groups relative to HFD group
OTU in Chow group changed by HFD was reversed by WEGL
0.0 0.0010 30.0
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Quantity
of OTU
4 2424 24
35 2018
18
32
17 30
Figure 4 | Continued.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8489 ARTICLE
NATURE COMMUNICATIONS | 6:7489 | DOI: 10.1038/ncomms8489 |www.nature.com/naturecommunications 7
& 2015 Macmillan Publishers Limited. All rights reserved.
gut microbiota of WEGL-treated animals may improve the
condition of HFD-fed mice, we transferred the microbiota of
WEGL-treated mice to HFD-fed mice, followed by examination
of obesity-related traits. Analysis of the cohort of donor mice
indicated that WEGL treatment reduced body weight and the
Firmicutes-to-Bacteroidetes ratio in the gut microbiota of HFD-
fed mice (Supplementary Fig. 9a,b), similar to the results shown
above (Figs 1a and 4c). Our results further showed that horizontal
faecal transfer from mice fed with chow (Chow-HFD),
Chowþ 8% WEGL (8% WEGL (Chow)-HFD), or HFDþ 8%
WEGL (8% WEGL (HFD)-HFD) reduced body weight,
epididymal and subcutaneous fat accumulation and liver weight
compared with faecal transfer from HFD-fed mice (HFD-HFD;
Fig. 5a–d). Faecal transfer from the Chowþ 8% WEGL group
produced the most robust effects on weight gain and fat
accumulation (Fig. 5a–c).
Expression of pro-inflammatory cytokines and lipogenic genes
was also reduced in hepatic and adipose tissues of HFD mice after
transfer of faeces derived from WEGL-treated animals (Fig. 6a–d
and Supplementary Fig. 10). Furthermore, the mRNA and
protein expression levels of tight junction proteins in the ileum
segment were also increased following the transfer of faeces from
WEGL-treated mice (Fig. 6e–g). Transfer of faeces from 8%
WEGL-chow-fed mice to HFD mice also produced statistically
significant changes in TNF-a expression (Fig. 6a), lipogenic genes
(Supplementary Fig. 10) and ileum tight junctions (Fig. 6e–g),
compared with faecal transfer from chow-fed mice. These results
suggest that the weight-lowering effects of WEGL in HFD-fed
mice may be due to modulation of the gut microbiota.
WEGL faecal transplants modulate gut microbiota composition.
In order to confirm that WEGL modulates the gut microbiota,
we examined the composition of intestinal bacteria following
faecal transfer from 8% WEGL-treated mice. In a separate
sequencing analysis, a total of 1,056,611 raw reads and an average
of 52,831±6,766 reads per sample were obtained. Subsequently, a
total of 458,093 effective reads was generated and each faecal
sample (n¼ 5 for each group) produced 22,905±3,039 effective
reads. Under this sequencing depth, rare phylotypes and most
diversity were also covered (Supplementary Fig. 11). In comparison
with mice that received faeces from HFD-fed mice, recipient
HFD-fed mice (n¼ 5 for each group) showed distinct microbiota
after faecal transplantation from Chow-, Chowþ 8% WEGL-
or HFDþ 8% WEGL-fed mice (Fig. 7a,b). Faecal transfer
from HFD mice produced Firmicutes to Bacteroidetes ratios and
50
45
40
35
30
25
20
0 1 2 3 4 5 6 7 8 (week)
2.5
2.0
1.5
1.0
0.5
0.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
2.0
1.5
1.0
0.5
0.0
a
a
a
b
a a
a
b
a a
b
c
Bo
dy
 w
e
ig
ht
 (g
) HFD→HFD
8% WEGL (Chow)→HFD
8% WEGL( HFD)→HFD
Chow→HFD
HF
D→
 
HF
D
8%
 W
EG
L (C
how
)→ 
HF
D
8%
 W
EG
L (H
FD
)→ 
HF
D
Ch
ow
→
 
HF
D
HF
D→
 
HF
D
8%
 W
EG
L (C
how
)→ 
HF
D
8%
 W
EG
L (H
FD
)→ 
HF
D
Ch
ow
→
 
HF
D
HF
D→
 
HF
D
8%
 W
EG
L (C
how
)→ 
HF
D
8%
 W
EG
L (H
FD
)→ 
HF
D
Ch
ow
→
 
HF
D
Ep
id
id
ym
al
 fa
t (g
)
Su
bc
ut
an
eo
us
 fa
t (g
)
Li
ve
r 
w
e
ig
ht
(g)
* *
* **
*
Figure 5 | Obesity and fat accumulation are reversed by faecal transplantation from WEGL-treated mice to HFD-fed mice. Eight-week-old HFD-fed
mice were colonized with faeces from different mouse groups for 8 weeks, followed by measurement of body weight (a) epididymal fat (b) subcutaneous
fat (c) and liver weight (d). Each group consisted of five mice. Body weight differences in a were analysed using unpaired two-tailed Student’s t-test
(*Po0.05, **Po0.01, ***Po0.001). Graph bars in b–d with different letters on top represent statistically significant results (Po0.05) based on Newman–
Keuls post hoc one-way ANOVA analysis, whereas data labelled with the same letter correspond to results that show no statistically significant differences.
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Figure 6 | Analysis of pro-inflammatory cytokines and intestinal tight junctions following faecal transplantation from WEGL-treated mice. Eight-week-
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Proteobacteria and Deferribacteres phyla levels that did not differ
from those of HFD-fed mice (Fig. 7c, compared with Fig. 4c). In
contrast, faeces transfer from Chow-, Chowþ 8% WEGL and
HFDþ 8% WEGL-fed mice produced values similar to those of
chow-fed or WEGL-treated mice (Fig. 7c, compared with Fig. 4c).
RDA analysis identified a total of 155 OTUs that were
significantly altered by faecal transplant from Chow- (126 OTUs),
Chowþ 8% WEGL- (71 OTUs) and HFDþ 8% WEGL-fed
groups (75 OTUs) compared with HFD-HFD mice
(Supplementary Data 4 and Supplementary Fig. 12). Among
these, M. shaedleri, E. fergusonii, L. lactis, C. scindens and
O. valericigenes, which were enhanced by HFD feeding (Fig. 4d),
were all reversed by faecal transfer from Chow-, Chowþ 8%
WEGL- and HFDþ 8% WEGL-fed mice (Fig. 7d,e). In addition,
Clostridium cocleatum, Bacteroides caccae, Eubacterium dolichum
and Coprobacillus cateniformis were altered after faecal trans-
plantation from the same three groups of mice (Fig. 7d,e, these
bacteria were not identified in the WEGL treatment experiments
shown in Fig. 4). Of note, while the HFD-induced reduction of P.
goldsteinii (Fig. 4d,e) was observed in HFD-HFD mice, this
species was induced by faecal transplantation from the other three
groups of mice (Fig. 7d,e). Interestingly, Akkermansia mucini-
phila, a potentially beneficial bacterial species, was only identified
in HFD-fed mice that received faeces from Chowþ 8% WEGL-
treated mice (Fig. 7d,e). These results indicate that WEGL
restores the gut microbiota of HFD mice to a composition similar
to those of chow-fed mice.
WEGL high molecular weight polysaccharides reduce obesity.
To identify the active ingredients of WEGL responsible for the
anti-obesity effects, we fractionated the mycelium extract into
four fractions (G1, G2, G3 and G4) on the basis of their molecular
weights (Table 1). As shown in Fig. 8a–e, fraction G1, which
1
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Figure 7 | Analysis of gut microbiota following faecal transplantation. Faecal transplantation from Chow-, HFD- and Chow/HFDþ8% WEGL-fed mice
was performed and relevant microbiota analysis was done as described in the Methods. (a) The plots shown were generated using the weighted version of
UniFrac-based PCoA. (b) Multivariate analysis of variance from PCoA matrix scores. (c) Bacterial taxonomic analysis of intestinal bacterium from each
mouse groups. (d) Heatmap showing the abundance of 155 OTUs significantly altered by Chow, Chowþ 8% WEGL and HFDþ8% WEGL transplanted
mice based on RDA analysis. (e) Represented bacterial taxa information (species, genus, family and phylum) of 155 OTUs from d are shown. White circles
and black diamonds indicate the OTUs that increased or decreased compared with HFD recipient mice.
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consisted of polysaccharides with molecular weight 4300 kDa
(Table 1) and a monosaccharide composition comprising 47.5%
mannose, 26.3% glucose and 16.9% galactose (Table 2), produced
significant anti-obesity effects on body weight, liver weight and
epididymal and subcutaneous fat in HFD-fed mice. Notably,
the extent of anti-obesity effects observed was similar to that
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produced by the whole WEGL mycelium extract (Fig. 8a–e).
In contrast, fraction G2 showed modest anti-obesity effects,
whereas no significant effect was observed for fractions G3 and
G4 (Fig. 8a–e). No significant change in mean energy intake, stool
fat or energy extraction was noted following treatment with the
polysaccharide fractions (Supplementary Fig. 13). These results
suggest that the anti-obesity effects of WEGL mycelium may be
due mainly to its high molecular weight polysaccharide fraction.
Discussion
Although previous studies have shown that G. lucidum lowers
serum glucose and produces beneficial effects on type 2 diabetes
mellitus in murine models6,41,42, the effects of this fungus on the
gut microbiota, inflammation and obesity had not been
investigated. Our study shows that G. lucidum mycelium
prevents dietary-induced obesity and alleviates inflammation by
modulating the composition of the gut microbiota and
maintaining intestinal barrier integrity. Our results thus reveal
that WEGL modulates the intestinal microbiota previously
reported to correlate with obesity43, but also identify the high
molecular weight polysaccharides (4300 kDa) as the major
bioactive ingredients responsible for these effects.
Our observations that WEGL produces significant changes in
the gut microbiota and the anti-obesity effects of WEGL are
transferrable through faecal transplantation support the concept
that obesity is associated with an altered gut microbiota. These
findings are consistent with the results of a recent study by
Ridaura et al.13 Using twins discordant for obesity as a model,
these authors observed that transfer of the gut microbiota of
obese individuals to HFD-fed mice conveyed larger weight gain
and higher levels of obesity-associated metabolic disorders than
faecal transfer from the individual’s lean twin. Our results suggest
that the gut microbiota can be modulated by dietary intervention
or faecal transfer, and that the WEGL mycelium extract may be
used as prebiotics to produce a specific gut microbiota associated
with reduced weight gain, inflammation and insulin resistance in
obese individuals.
The current model of HFD-induced chronic inflammation and
obesity-related disorders is explained largely by dysbiosis of the
gut microbiota and increased levels of LPS in the blood, a
condition called metabolic endotoxemia19. The intestinal lumen
is a reservoir of LPS from Gram-negative bacteria that include
Escherichia spp.20 In a state of intestinal dysbiosis as seen in
HFD-fed animals, the intestinal tube may gradually become leaky,
allowing the LPS of Gram-negative bacteria to enter the entero-
hepatic circulation. Low concentrations of LPS in blood may
cause systemic and targeted inflammation in HFD-fed mice and
obese humans through activation of TLR4 signalling in various
cells22. Our results indicate that WEGL supplementation
improves gut barrier integrity, reduces endotoxemia, decreases
TLR4 signalling and decreases inflammation in obese mice fed
with a HFD. The beneficial effects induced by WEGL treatment
may therefore be attributed to specific alterations in the gut
microbiota (for example, reduction of Escherichia spp. such as
E. fergusonii) and to maintenance of gut barrier integrity.
Macrophages found within adipose tissues exhibit two different
activation profiles consisting of the M1 and M2 types44.
LPS-induced M1 macrophages accumulate around dying
adipocytes and hepatocytes and secrete pro-inflammatory
cytokines, providing a mechanism to explain how obesity may
propagate inflammation45. We observed that WEGL treatment
reduces the number of macrophages and decreases MCP-1
expression in hepatic and adipose tissues of HFD-fed mice
(Supplementary Fig. 3a–c). Furthermore, an increase of IL-10
expression (Fig. 2d) and Treg cells in liver and adipose tissues
(Supplementary Fig. 3d,e) was also observed in WEGL-treated
mice. In addition to macrophages and Treg cells, other immune
cells such as NKT and B cells46–48 may also contribute to the anti-
obesity effects observed here.
The gut microbiota of obese humans and animals is associated
with decreased levels of intestinal Bacteroidetes and increased
levels of Firmicutes, indicating that these major phyla may play a
role in obesity-related inflammation16,49. Accordingly, prebiotics
feeding with the plant hemicellulose compound arabinoxylan
reverses the Bacteroides-to-Firmicutes ratio and reduces
obesity50. We observed that 8% WEGL supplementation in
HFD-fed mice restored the Firmicutes to Bacteroidetes ratio to
that observed in chow-fed mice (Fig. 4c). Intriguingly, the
probiotic Bifidobacterium spp., which were previously reported to
reduce obesity51,52, were not detected in the present study.
This observation suggests that WEGL may produce anti-obesity
effects by altering the Firmicutes-to-Bacteroidetes ratio as
well as modifying the levels of other specific bacterial species
(Supplementary Data 2 and 3).
A previous study showed that chitin-glucan fibres modulate
Clostridium cluster XIVa (Roseburia spp.) in the gut microbiota
of HFD-fed mice53. Bacteria belonging to Clostridium clusters
XIVa, XVIII and IV, which lack prominent toxins and virulence
factors, were found earlier to modulate host fatty acid
metabolism, induce Treg cell activity and attenuate colitis54.
Furthermore, Eubacterium spp. induced by prebiotic
oligosaccharides produce beneficial effects on animal hosts55,
highlighting the potential probiotic effect of these species. Our
results demonstrate that WEGL supplementation enhances
bacterial levels of Clostridium clusters IV, XVIII and XIVa
(Roseburia spp.), and Eubacterium spp. in HFD-fed obese mice
(Fig. 4d,e and Supplementary Data 2). These results indicate that
the effects of WEGL may be at least partially due to an increase in
the populations of these beneficial species. WEGL feeding also
decreased several bacterial species associated with inflammation
and obesity. For instance, E. fergusonii, which is asso-
ciated with HFD-induced inflammation20, was reduced
following WEGL treatment (Fig. 4d,e and Supplementary Data
Table 1 | Molecular weight analysis of polysaccharide
subfractions isolated from WEGL mycelium.
Subfraction Component Molecular
weight (MW)
Percentage
(%)
G1 Polysaccharide 4300 kDa 33.7
G2 Polysaccharide 10–300 kDa 15.6
G3 Polysaccharide o10 kDa 4.0
G4 Mono-, di-,
oligosaccharide
Undetermined 46.8
Polysaccharides were analysed from a 100-ml solution of 20% WEGL (w/v).
Table 2 | Monosaccharide composition of WEGL-G1
subfraction (4300 kDa).
Man Glc Gal GlcN Ara GalN Rha Fuc
Concentration
(mg l 1)
19.16 10.6 6.82 0.44 1.17 ND 0.99 1.18
Percentage (%) 47.5 26.3 16.9 1.1 2.9 ND 2.5 2.9
Ara, arabinose; Fuc, fucose; Gal, galactose; GalN, galactosamine; Glc, glucose; GlcN,
glucosamine; Man, mannose; ND, not detected; Rha, rhamnose.
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2). Oscillibacter spp. were also reported to increase in HFD-fed
mice compared with chow-fed mice, and these bacteria showed a
negative relationship with the expression of intestinal tight
junction proteins40. Consistent with these observations, the 8%
WEGL treatment reversed the percentage of Oscillibacter spp. in
the gut microbiota of HFD-fed mice to a percentage similar to
that seen in chow-fed mice (Fig. 4d,e and Supplementary Data 1
and 2). In addition, Mucispirillum spp. belonging to
Deferribacteres, which are known to colonize the mucus layer,
increased in HFD-fed mice compared with chow-fed mice56.
In contrast, Mucispirillum spp. were reduced by WEGL in HFD
mice in the present study (Fig. 4d,e and Supplementary Data 2).
Therefore, WEGL may prevent HFD-induced obesity by
modulating the composition of the gut microbiota in multiple
ways57. Nonetheless, the hypothesis that WEGL may also directly
affect pro-inflammatory signalling pathways such as TLR2,
which also controls adiposity and insulin resistance58, cannot
be ruled out.
In addition to modulation of the microbiota composition, our
in vivo experiments demonstrate that the administration of
WEGL also reduces expression of genes involved in fatty acid
synthesis and reduces insulin resistance in HFD-fed mice. These
results suggest that the effects of WEGL may be due to
modulation of lipogenic gene expression. Moreover, a previous
study demonstrated that over-production of pro-inflammatory
cytokines such as TNF-a, IL-1b, IL-6 and MCP-1 in obese
animals may be responsible for the development of chronic
inflammation and insulin resistance, due at least in part to IRS-1
phosphorylation (on serine 307; ref. 31). In the present study,
WEGL treatment induced the de-phosporylation of IRS-1 and
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Figure 8 | Effect of WEGL polysaccharide fractions on body weight and fat accumulation in HFD-fed mice. Mice fed with chow or HFD were treated
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enhanced phosphorylation of Akt, leading to improved insulin
sensitivity. Thus, WEGL may not only regulate expression of
lipogenic genes, but also affect signalling pathways involved in
insulin resistance.
Previous studies have highlighted the importance of short-
chain fatty acids (SCFAs) such as acetate, propionate and butyrate
in amelioration of chronic inflammatory diseases and promotion
of colonocyte health59. SCFAs were reported to suppress
production of pro-inflammatory cytokines, enhance IL-10
expression and activate Treg cells, leading to amelioration of
colitis60. SCFAs are produced from fermentation of
polysaccharides and some other prebiotics by gut bacteria such
as Bacteroides spp.50 As the percentage of Bacteroides was
enhanced by treatment of HFD mice with 8% WEGL, it is
possible that the amount of SCFAs may also increase in this case.
It remains to be determined whether SCFAs are affected or not by
WEGL and whether these molecules contribute to the anti-
inflammatory effect of WEGL.
Notably, our results show that high molecular weight
polysaccharides (4300 kDa) isolated from WEGL produce
significant anti-obesity effects in HFD-fed mice. Concerning the
possible mechanism of action of polysaccharides from WEGL,
previous studies suggest that intestinal bacteria possess distinct
polysaccharide preferences and that these molecules may favour
the growth of specific bacterial species in the gut microbiota61.
Collectively, our results suggest that both WEGL and its high
molecular weight polysaccharides may be used as prebiotics to
reduce body weight gain, chronic inflammation and insulin
resistance in obese individuals.
Methods
Murine and fungal strains. Animal experiments were approved and performed in
accordance with the guidelines of Institutional Animal Care and Use Committee of
Chang Gung University (IACUC; Approval No. CGU11-117). Mice of the C57BL/
6NCrlBltw genetic lineage were purchased from Biolasco (Taiwan) and kept under
controlled light conditions (12 h light–dark cycle), with free access to food and
water. Eight-week-old male mice were randomly distributed into six groups con-
taining five to seven animals each (see the legend of Figs 1,4–6,8). Mice were
housed in groups of three or four animals per cage, and were fed with either a
standard chow diet (13.5% of energy from fat; LabDiet 5001; LabDiet, USA) or a
high-fat diet (60% of energy from fat; TestDiet 58Y1; TestDiet, USA). The G.
lucidum strain initially isolated and characterized at Chang Gung Biotechnology
and the water extract of cultured mycelium were processed as described before62.
Briefly, the water extract was prepared by mixing 400 g of dried G. lucidum
mycelium in 10 l of water before agitation at 150 r.p.m. for 30min at 121 C. The
solution was cooled to room temperature (22 C), followed by centrifugation at
5,894g for 30min at 4 C using a Sorvall RC 3C Plus centrifuge (Thermo Fisher
Scientific, USA). The supernatant was concentrated using a Buchi R220 Rotavapor
vacuum concentrator (Buchi, Switzerland) at 65 C to obtain a final volume of 2 l.
The extract was sterilized at 121 C for 20min, followed by storage at 4 C in dark
glass bottles. The mycelium consisted ofo5% crude fibre; 410% polysaccharides;
crude proteins at 38.78 g per 100 g; crude fat at 2.41 g per 100 g; carbohydrates at
41.99 g per 100 g; amino acids at 5.2 g per 100 g; and sodium at 76.39mg per 100 g.
Calories were measured at 345 kcal per 100 g. Each group of mice was fed for 2
months with chow diet or HFD, plus daily administration of 100 ml of either water
or WEGL at 2, 4 or 8% (w/v) by intragastric gavage. Mean energy intake was
assessed by converting the amount of food consumed into calories using the
information provided by the manufacturer (LabDiet 5001 and TestDiet 58Y1).
Preparation of WEGL polysaccharide subfractions. WEGL polysaccharide
fractions were provided by Chang Gung Biotechnology. Briefly, 100ml of WEGL
extract was mixed with 600ml of 95% ethanol (v/v) before incubation for 16 h at
4 C. The solution was centrifuged at 4,500g for 20min at 4 C (Sorvall RC 3C Plus
centrifuge; Thermo Fisher Scientific, USA). The first supernatant was decanted and
100ml of 70% cold ethanol was added to produce a pellet. The solution was
centrifuged as above and the second supernatant was decanted. This operation was
repeated three times. The first and second supernatants were pooled to obtain a
volume of 1,050ml (fraction G4). The precipitate pellet containing crude poly-
saccharides was mixed with 1,000ml of distilled water and the material was dis-
solved completely. The solution of crude polysaccharides was concentrated to a
final volume of 700ml using an R220 vacuum concentrator (Bu¨chi, Switzerland) at
65 C to remove residual alcohol. Distilled water was added into the crude poly-
saccharide solution to obtain a final volume of 2,400ml. The solution was filtered
using the Spectrum KrosFlo system with 0.2 mm hollow fibre (1,500 cm2, PES;
Spectrum Laboratories, USA). The transmembrane pressure was set at 15 p.s.i. A
total of 1,800ml of distilled water was added during filtration of the crude poly-
saccharide solution. The retentive filtrate (650ml) was preserved (G1-1). The
solutions were filtrated using a 300 kDa cassette membrane (Minimate TFF Cap-
sule; Pall, USA). A total of 600ml of distilled water was added during filtration. The
retentive filtrate (950ml) was gathered (G1-2). The G1-1 and the G1-2 filtrates
were combined to obtain a volume of 1,600ml (G1). The permeated filtrate was
filtrated with a 10 kDa cassette membrane. A total of 600ml of distilled water was
added during filtration. The retentive filtrate (970ml) (G2) and 3,600ml of the
permeated filtrate (G3) were obtained. The G1, G2, G3 and G4 solutions were
concentrated to a final volume of 100ml using the vacuum concentrator.
Faecal transplantation. Faecal transplant was performed based on an established
protocol63. Briefly, 8-week-old male donor mice (n¼ 5 per diet group) were fed
with Chow, Chowþ 8% WEGL, HFD or HFDþ 8% WEGL for 3 months. After 4
weeks of feeding, stools were collected daily for the subsequent 2 months under a
laminar flow hood in sterile conditions. Stools from donor mice of each diet group
were pooled and 100mg was resuspended in 1ml of sterile saline. The solution was
vigorously mixed for 10 s using a benchtop vortex (Vortex-Genie 2, Scientific
Industries, USA; speed 9), before centrifugation at 800g for 3min. The supernatant
was collected and used as transplant material as described below. Fresh transplant
material was prepared on the same day of transplantation within 10min before oral
gavage to prevent changes in bacterial composition. Eight-week-old male recipient
mice (n¼ 5 for each transplant group) were fed with HFD and inoculated daily
with fresh transplant material (100 ml for each mouse) by oral gavage for 2 months,
before being killed for subsequent analysis. Analysis of body weight and gut
microbiota of the donor mice (Supplementary Fig. 9a,b) indicated that the 4-week-
long diet treatments used for this cohort of mice produced changes similar to those
of the 2-month-long treatments (Figs 1a and 4c).
Antibodies. Antibodies against IkB-a (nuclear factor of kappa light polypeptide
gene enhancer in B cells inhibitor alpha; 1:1,000; 9242L), JNK (c-Jun N-terminal;
1:1,000; 9252L), phosphorylated JNK (1:1,000; 4668S), phosphorylated IRS-1
(insulin receptor substrate-1; phosphorylation on serine 307; 1:1,000; 2381S), IRS-1
(1:1,000; 2382L), Akt (1:1,000; 4691L), phosphorylated Akt (phosphorylation on
serine 473; 1:1,000; 4060L) and TLR4 (1:1,000; 2219) were purchased from Cell
Signaling Technology (USA). Antibodies against zonula occludens-1 (ZO-1; 1:250;
61–7,300) and occludin (1:250; 71–1,500) were obtained from Invitrogen (USA).
Secondary antibodies (anti-rabbit IgG, Hþ L; 1:10,000 and 1:2,000 for primary
antibodies from Cell Signaling Technology and Invitrogen, respectively;
111-035-003) were purchased from Jackson ImmunoResearch (USA). Antibody
against b-actin (1:20,000; NB600-501) and secondary antibody anti-mouse IgG
(1:20,000; sc-2005) were purchased from Novus Biologicals (USA) and Santa Cruz
Biotechnology (USA), respectively. FITC-conjugated anti-F4/80 (1:100; 11-4801;
eBioscience, USA), PE-conjugated anti-CD11b (1:100; 557397; BD Pharmingen,
USA), anti-CD11c (1:100; 557401; BD Pharmingen), PE-conjugated anti-CD4
(1:100; 557308; BD Pharmingen), PerCp-Cy5.5-conjugated anti-CD25 (1:100;
551071; BD Pharmingen) and Alexa Flour 488-conjugated anti-Foxp3 (1:100;
560403; BD Pharmingen) antibodies were also used.
Determination of energy and fat in faeces. Measurements were made based on a
protocol reported previously64. The energy density was determined using an
adiabatic bomb calorimeter (Gallenkamp, UK). Total faecal lipids were extracted as
described previously65. Briefly, dried faecal samples were homogenized once with
heptane/diethylether/ethanol (1:1:1, vol/vol) and twice with heptane/diethylether/
ethanol/water (1:1:1:1, vol/vol). Supernatants were collected in glass vials that had
been weighed beforehand. Total lipid amount in each supernatant was measured
gravimetrically after solvent evaporation and was expressed as a percentage of the
weight of the starting faecal sample.
Oil red O staining. Frozen liver sections (6-mm thick) were stained with Oil Red O
(Sigma, USA) for 20min, and then counter-stained with haematoxylin for 1min.
Sections were examined under light microscopy. A total of 20 tissue sections were
analysed for each animal.
Oral glucose tolerance test. Overnight-fasted mice were given glucose by oral
gavage (3 g kg 1, 66% solution), and measurement of homeostatic model assess-
ment-insulin resistance was performed as described before20. Blood glucose was
determined with a glucose meter (Roche Diagnostics, Switzerland) using blood
collected from the tip of the tail vein.
Biochemical analyses. Serum LPS quantification was performed using a com-
mercial kit based on the use of a Limulus amaebocyte extract (Lal kit; Cambrex Bio
Science, USA). Samples were diluted 1:20 and heated for 10min at 70 C. Serum
insulin concentrations were determined in 5 ml of serum using a commercial ELISA
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kit (Mercodia, Sweden) based on the manufacturer’s instructions. Serum FFA were
determined using a commercial detection kit (Biovision, USA).
Quantitative real-time reverse-transcription PCR. Total RNA was isolated using
a total tissue RNA isolation kit (Geneaid, Taiwan). Equal amounts of total RNA
were used to synthesize cDNA with the Quant II fast RT kit (Tools, Taiwan).
Quantitative real-time reverse-transcription PCR (qRT–PCR) was performed in
triplicate using SYBR Green, 384-well plates and the LightCycler 480 Real-Time
PCR System (Roche Diagnostics). Each well was loaded with a total of 10 ml
containing 1.5 ml of cDNA, 1 ml of target primers, 1.5 ml of water and 5 ml of Kapa
SYBR Fast Master Mix. Hot-start PCR was performed for 50 cycles, with each cycle
consisting of denaturation for 15 s at 94 C, annealing for 30 s at 60 C and elon-
gation for 30 s at 72 C. The Roche LightCycler software (version 1.5.0, Roche
Diagnostics) was used for data analysis. Relative quantification was done using the
2DDCT method66. Expression was normalized against the housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase. Mean expression levels of chow-fed
mice were set as 100%. The primers used are shown in Supplementary Table 1.
Western blotting. One hundred mg of adipose, liver or intestine tissue were
homogenized in a commercial Pro-Prep Protein Extraction Solution (Intron Bio-
technology, South Korea). Total protein lysates were fractionated on a 10% sodium
dodecyl sulfate–polyacrylamide gel and electro-blotted onto polyvinylidene
difluoride membranes (Immobilon TM-P; Millipore, USA). Membranes were
blocked with 5% non-fat milk for 1 h at room temperature in TBST buffer (Tris
10mM, NaCl 150mM, pH 7.6, 0.1% Tween 20) and probed with primary anti-
bodies overnight at 4 C. Membranes were then incubated with horseradish per-
oxidase-conjugated secondary antibody. The dilutions of primary and secondary
antibodies were described in the Antibody section above. Protein bands were
developed using enhanced chemiluminescence (Millipore). The original immu-
noblots were provided in Supplementary Fig. 14.
Morphometry analysis of epididymal adipose tissues. Freshly isolated epidi-
dymal adipose tissues from wild-type or WEGL-treated mice were fixed overnight
in 10% formalin, followed by dehydration, embedding in paraffin, and sectioning.
Sections of 8 mm were stained with haematoxylin and eosin, and cell size was
analysed using the Image J software (National Institutes of Health, USA).
Flow cytometry analysis. Epididymal adipose and hepatic tissues were rinsed in
saline, minced into fine pieces and digested with collagenase (Sigma, USA) in
Krebs–Henseleit–HEPES buffer (Sigma, USA; pH 7.4) supplemented with
20mgml 1 of BSA and 2mM glucose. Incubation was performed at 37 C in a
shaker for 45min. The samples were passed through a mesh and fractionated by
brief centrifugation (1,000g). The pellets or the floating cells were collected to
obtain the stromal–vascular fraction or adipocytes in adipose tissues, respectively.
Cells in the stromal–vascular fraction and liver fractions were lysed in Pharm Lyse
buffer for 30min at 4 C and resuspended in Pharmingen stain buffer (Becton
Dickinson, USA). Cells were incubated with the commercial antibody 2.4G2, which
reacts against the FcgII and FcgIII murine receptors (Becton Dickinson, USA) for
10min and then with primary antibodies or the matching control isotypes for
30min at 4 C. The cells were rinsed twice and resuspended in Pharmingen stain
buffer. Flow cytometry analysis was performed using a FACSCalibur (Becton
Dickinson, USA). Data analysis was performed using the Kaluza flow cytometry
analysis software (Beckman Coulter, USA). Macrophages were identified either as
F4/80 and CD11c double-positive cells in adipose tissues or as F4/80 and CD11b
double-positive in the liver. CD4, CD25 and transcription factor Foxp3 were
analysed for Treg cells.
Cytokine measurements. IL-1b, IL-6 and TNF-a protein levels were measured
using commercial ELISA kits (R&D Systems, USA).
Gut microbiota analysis. Stool samples were snap-frozen in liquid nitrogen before
storage at  80 C. DNA was extracted using a faecal DNA isolation kit (MoBio
Laboratories, USA). For each caecal stool sample, the 16S rRNA gene comprising
V3–V5 regions was amplified using a composite forward primer and a reverse
primer containing a unique 10-base barcode to tag each PCR product. For each
sample, a 50 ml PCR mix was prepared containing 25 ng DNA template, 5 KAPA
HiFi Buffer, 10mM KAPA dNTP Mix, 1U ml 1 KAPA HiFi DNA Polymerase
(KAPA Biosystems, USA) and 0.3 mM of composite primer pairs. The PCR reaction
conditions consisted of 95 C for 3min, followed by 15–25 cycles of 98 C for 20 s,
45 C for 15 s and 72 C for 15 s, and a final extension of 72 C for 1min. The
composite primer pairs consisted of the forward primer (50-GCCTTGCCAGCC
CGCTCACTCCTACGGGAGGCAGCAG-30)—a composite of 454 primer B
(underlined) and the universal bacterial primer 338F (italics)—and the reverse
primer (50-GCCTCCCTCGCGCCATCAGNNNNNNNNNNCCGTCAATTCMTT
TGAGTTT-30)—a composite of 454 primer A (underlined), a unique 10-base
barcode (NNNNNNNNNN) and the broad-range bacterial primer 907R (italics).
Replicate PCRs were pooled and amplicons were purified using the QiaQuick PCR
Purification Kit (Qiagen, USA). PCR products were sequenced on a 454 FLX
pyrosequencer platform according to 454 Roche recommended procedures. High-
quality reads for bioinformatics analysis were selected and all of the effective reads
from all samples were clustered into OTUs based on 97% sequence similarity
according to 454 SOP67. Briefly, quality control criteria for selecting raw reads of
high quality included removal of sequences that lacked V3–V5 primers or barcode
sequence (barcode sequence poorly matched or was not identified) as well as
sequences that contained a short variable region (o90 bp) or undetermined bases
(42 bases) in the V3–V5 variable region. De-noising criteria comprised (1) using a
50-bp sliding window to reduce sequencing error and (2) an average quality score
of 35 within that window for sequence trimming. All high-quality sequences were
aligned using the nearest alignment space termination multi-aligner in SILVA-
compatible database alignment. Reads that did not align to the anticipated region
of the reference alignment were removed. Chimera sequences identified using the
UCHIME algorithm68 were removed. All reads were classified using a Bayesian
classifier with homemade RDP database. Reads that could not be classified at the
kingdom level were removed. Alpha diversity analysis including rarefaction
analysis and Shannon index were calculated using QIIME69. Fast UniFrac PCoA
was performed with the phylogenetic tree constructed by inserting the
representative of each OTU also generated using QIIME69. According to published
statistical methods70, the statistical significance of the separation among animal
groups in PCoA scores plots was assessed by multivariate analysis of variance test
with differences in physiological and biochemical values for statistical significance.
Normally distributed data were analysed by analysis of variance (ANOVA) using
Tukey’s post hoc test (SPSS, USA). The relative abundance of each OTU (log10-
transformed) was used to construct RDA models and OTUs that were different
between animal groups were assessed with Canoco for Windows 4.5
(Microcomputer Power, USA) according to the manufacturer’s instructions.
Statistical significance was assessed using the Monte Carlo Permutation Procedure
with 499 random permutations.
Determination of bacteria by quantitative real-time PCR. Using bacteria-spe-
cific primers described in Supplementary Table 1, abundance of Firmicutes, Bac-
teroidetes and total bacteria in faecal stool from each diet group at indicative time
point was determined by 2DDCT method-based quantitative real-time PCR66. The
relative abundance of Firmicutes and Bacteroidetes was normalized to total bacteria
for calculation of Firmicutes-to-Bacteroidetes ratio.
Statistical analysis. Data obtained from three replicate experiments are shown as
means±s.e.m. Differences in body weight were assessed using the unpaired two-
tailed Student’s t-test. Data sets that involved more than two groups were assessed
by one-way ANOVA followed by Newman–Keuls post hoc tests (see the legend of
Figs 1–3,5,6,8). Next generation sequencing analysis was assessed using Tukey’s
honest significant difference post hoc tests. A P value of 0.05 was considered
statistically significant. In the figures, the data with different superscript letters are
significantly different based on post hoc ANOVA statistical analysis. SPSS version
17.0 was used.
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